Literature DB >> 6610105

Binding of complement subcomponent C1q to mouse IgG1, IgG2a and IgG2b: a novel C1q binding assay.

R J Leatherbarrow, R A Dwek.   

Abstract

A C1q binding assay is presented which is suitable for use in comparison of the binding ability of different antibodies, and which allows the quantitative determination of their binding constants. The assay system uses IgG bound to a hapten-derivatized Affigel support. No non-specific binding is observed to a DNP-derivatized support, allowing the use of anti-DNP antibodies. With mouse anti-DNP hybridoma IgGs it was found that C1q binding followed the series IgG2a greater than IgG2b much greater than IgG1, in accordance with the complement fixing ability of these subclasses. Since it is relatively simple to couple any antigen to Affigel , this assay system should be generally applicable to any antibody-antigen system.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6610105     DOI: 10.1016/0161-5890(84)90103-2

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  14 in total

1.  Immunization of mice with live-attenuated late liver stage-arresting Plasmodium yoelii parasites generates protective antibody responses to preerythrocytic stages of malaria.

Authors:  Gladys J Keitany; Brandon Sack; Hannah Smithers; Lin Chen; Ihn K Jang; Leslie Sebastian; Megha Gupta; D Noah Sather; Marissa Vignali; Ashley M Vaughan; Stefan H I Kappe; Ruobing Wang
Journal:  Infect Immun       Date:  2014-09-29       Impact factor: 3.441

2.  Quantitative analysis of the interaction between immune complex and C1q complement subcomponent. The role of interdomain interactions in rabbit IgG in binding of C1q to immune precipitates.

Authors:  F Vonderviszt; J Török; S Lakatos; F Kilár; P Závodszky
Journal:  Biochem J       Date:  1987-04-15       Impact factor: 3.857

3.  The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.

Authors:  A Morgan; N D Jones; A M Nesbitt; L Chaplin; M W Bodmer; J S Emtage
Journal:  Immunology       Date:  1995-10       Impact factor: 7.397

4.  Dectin immunoadhesins and pneumocystis pneumonia.

Authors:  David M Ricks; Kong Chen; Mingquan Zheng; Chad Steele; Jay K Kolls
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

Review 5.  Antibody-mediated neutralization of flaviviruses: a reductionist view.

Authors:  Kimberly A Dowd; Theodore C Pierson
Journal:  Virology       Date:  2011-01-20       Impact factor: 3.616

6.  The NYCBH vaccinia virus deleted for the innate immune evasion gene, E3L, protects rabbits against lethal challenge by rabbitpox virus.

Authors:  Karen L Denzler; Amanda D Rice; Amy L MacNeill; Nobuko Fukushima; Scott F Lindsey; Greg Wallace; Andrew M Burrage; Andrew J Smith; Brandi R Manning; Daniele M Swetnam; Stacey A Gray; R W Moyer; Bertram L Jacobs
Journal:  Vaccine       Date:  2011-08-12       Impact factor: 3.641

7.  Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils.

Authors:  N Zimmermann; M L McBride; Y Yamada; S A Hudson; C Jones; K D Cromie; P R Crocker; M E Rothenberg; B S Bochner
Journal:  Allergy       Date:  2008-09       Impact factor: 13.146

8.  Transmission blockade of Plasmodium falciparum malaria by anti-Pfs230-specific antibodies is isotype dependent.

Authors:  W Roeffen; F Geeraedts; W Eling; P Beckers; B Wizel; N Kumar; T Lensen; R Sauerwein
Journal:  Infect Immun       Date:  1995-02       Impact factor: 3.441

9.  Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models.

Authors:  Roberto Di Niro; Federica Ziller; Fiorella Florian; Sergio Crovella; Marco Stebel; Marco Bestagno; Oscar Burrone; Andrew R M Bradbury; Paola Secco; Roberto Marzari; Daniele Sblattero
Journal:  BMC Biotechnol       Date:  2007-08-01       Impact factor: 2.563

10.  Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.

Authors:  C I Bindon; G Hale; M Brüggemann; H Waldmann
Journal:  J Exp Med       Date:  1988-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.